A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...
The Centers for Medicare & Medicaid Services has successfully negotiated agreements with two drug manufacturers to participate in the newly created Cell and Gene Therapy Access Model. Vertex ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The two Massachusetts companies ...
Two FDA-approved gene therapies, Lyfgenia and Casgevy, will be offered through an outcomes-based Medicaid model launching in January 2025. The initiative ties payments to treatment effectiveness, ...
Bluebird bio (NASDAQ:BLUE) and Vertex Pharmaceuticals (NASDAQ:VRTX) have entered into outcome-based agreements with the Centers for Medicare & Medicaid Services aimed at expanding patient access to ...
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) ...
Vertex Pharmaceuticals Incorporated VRTX announced that it has entered into a licensing and collaboration agreement with France-based biotech company, TreeFrog Therapeutics, to optimize the production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback